Dr. Michelle Geller has spent the last 12 years of her career at Amgen, currently as an Executive Medical Director in Global Patient Safety and a Safety Therapeutic Area Head for the Immuno Oncology TA. She has also led various other product and process teams in the Amgen Global Patient Safety function, including the Bone and Cardiovascular Therapeutic Areas, and as the Head of Safety Management including Signal and Risk Management, Safety Governance, Periodic Reports and Medical Review to name a few. Michelle also worked in Scientific Affairs at Novartis as her first Pharmaceutical Industry role. Prior to her roles in Industry, she spent 10 years in Academic Clinical Practice at Mount Sinai and UCLA in Internal Medicine and Women's Health.